(R)-Ambrisentan-d3

CAS No. 1007358-76-0

(R)-Ambrisentan-d3( —— )

Catalog No. M23102 CAS No. 1007358-76-0

(R)-Ambrisentan-d3 is the deuterated version of (R)-Ambrisentan (A575873), which is the R-isomer impurity of Ambrisentan (A575860) that is a nonpeptide endothelin ETA receptor antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 468 In Stock
25MG 1020 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (R)-Ambrisentan-d3
  • Note
    Research use only, not for human use.
  • Brief Description
    (R)-Ambrisentan-d3 is the deuterated version of (R)-Ambrisentan (A575873), which is the R-isomer impurity of Ambrisentan (A575860) that is a nonpeptide endothelin ETA receptor antagonist.
  • Description
    (R)-Ambrisentan-d3 is the deuterated version of (R)-Ambrisentan (A575873), which is the R-isomer impurity of Ambrisentan (A575860) that is a nonpeptide endothelin ETA receptor antagonist, used as antihypertensive drug.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1007358-76-0
  • Formula Weight
    378.42
  • Molecular Formula
    C22H22N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Riechers, H., et al.: J. Med. Chem., 39, 2123 (1996); Billman, G.E., et al.: Curr. Opin. Invest. Drugs, 3, 1483 (2002); Vatter, H., et al.: Clin. Neuropharmacol., 26, 73 (2003)
molnova catalog
related products
  • 16beta-Methyl-16alph...

    16beta-Methyl-16alpha,17alpha-epoxypregnenolone

  • Icosabutate

    Icosabutate (NST-4016) is an orally active derivative of eicosapentaenoic acid that inhibits hepatic inflammation and fibrosis in NASH, improves cardiovascular risk profiles in statin-treated patients with residual hypertriglyceridemia, lowers triglycerides, and may be useful in studies of liver fibrosis and atherosclerosis.

  • FTO-IN-3

    FTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.